<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03652116</url>
  </required_header>
  <id_info>
    <org_study_id>PostCSLA</org_study_id>
    <nct_id>NCT03652116</nct_id>
  </id_info>
  <brief_title>Bupivacaine Verus Pethidine for Post Cesarean Section Pain Relief</brief_title>
  <official_title>Subrectal and Subcutaneous Wound Infiltration With Bupivacaine Versus Pethidine for Postcesarean Section Pain Relief: a Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to compare between the effect of wound infiltration with bupivacaine
      or pethidine for post cesarean section pain relief.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 21, 2017</start_date>
  <completion_date type="Actual">August 1, 2018</completion_date>
  <primary_completion_date type="Actual">June 10, 2018</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Participants will be randomized to local infiltration of cesarean section wound with either bupivacaine or pethidine; with follow up of postoperative pain relief.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Postoperative wound pain: VAS</measure>
    <time_frame>first 24 hours postoperatively</time_frame>
    <description>Postoperative wound pain will be assessed using visual analogous scale (VAS) ranging from 0 (no pain) to 10 (worst pain imaginable). Mean values will be calculated and compared between the three groups</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total dose of opioid drugs needed</measure>
    <time_frame>first 24 hours postoperatively</time_frame>
    <description>Total dose of extra opioid drugs needed to achieve postoperative analgesia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of nausea and vomiting</measure>
    <time_frame>first 24 hours postoperatively</time_frame>
    <description>Number of patients experiencing nausea and vomiting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of urine retention</measure>
    <time_frame>first 24 hours postoperatively</time_frame>
    <description>Number of patients experiencing urinary retention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of hypotension</measure>
    <time_frame>first 24 hours postoperatively</time_frame>
    <description>Number of patients experiencing hypotension</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">78</enrollment>
  <condition>Obstetric Pain</condition>
  <arm_group>
    <arm_group_label>Bupivacaine Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients delivered by cesarean section followed by wound infiltration by bupivacaine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pethidine Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients delivered by cesarean section followed by wound infiltration by pethidine.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Wound infiltration by Bupivacaine</intervention_name>
    <description>Subcutaneous and subrectal infiltration with 0.25 % Bupivacaine diluted in 20 ml normal saline before closure of the wound</description>
    <arm_group_label>Bupivacaine Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Wound infiltration by Pethidine</intervention_name>
    <description>Subcutaneous and subrectal infiltration with 50 mg pethidine diluted in 20 ml normal saline before closure of the wound</description>
    <arm_group_label>Pethidine Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Mode of delivery: Cesarean section.

          -  Gestational age: 37-40 weeks.

          -  Type of anaesthesia: Spinal anaesthesia.

          -  No past history of any medical disorder or other medical complications during
             pregnancy.

        Exclusion Criteria:

          -  Women with known hypersensitivity to bupivacaine or pethidine.

          -  Women delivered vaginally.

          -  Women delivered under general anaesthesia.

          -  Women with known neurological or psychological disease.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohamed Samy, MD</last_name>
    <role>Study Director</role>
    <affiliation>M Samy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ain SHams Maternity Hospital</name>
      <address>
        <city>Cairo</city>
        <state>Abbaseya</state>
        <zip>002</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>August 28, 2018</study_first_submitted>
  <study_first_submitted_qc>August 28, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 29, 2018</study_first_posted>
  <last_update_submitted>August 28, 2018</last_update_submitted>
  <last_update_submitted_qc>August 28, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>Sarah Safwat</investigator_full_name>
    <investigator_title>Lecturer in Obstetrics and Gynecology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Labor Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meperidine</mesh_term>
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

